

# Expert Perspectives on the Evolving SGLT Inhibition Treatment Landscape

SATURDAY, SEPTEMBER 28, 2024 | 7:15 PM – 8:15 PM ET

REGISTRATION AND MEAL: 6:45 PM | PRESENTATION: 7:15 PM

SIGNIA HOTEL ATLANTA, 159 NORTHSIDE DR NW  
ATLANTA, GEORGIA | ROOM: TRIUMPH E

HYBRID 

## CHAIR



**Zachary Cox, PharmD**  
Professor of Pharmacy  
Lipscomb University College of Pharmacy  
Nashville, Tennessee

## FACULTY



**Biykem Bozkurt, MD, PhD**  
The Mary and Gordon Cain Chair  
in Cardiology  
Professor of Medicine  
Senior Dean of Faculty  
Baylor College of Medicine  
Director  
Winters Center for Heart Failure Research  
Associate Director  
Cardiovascular Research Institute  
Baylor College of Medicine  
Houston, Texas



**Ileana L Piña, MD, MPH**  
The Robert Stein Chair of Quality  
and Safety for the Cardiovascular  
Service Line  
Professor of Medicine  
Cardiology, Heart Failure/Transplant  
Sidney Kimmel Medical College  
at Thomas Jefferson University  
Philadelphia, Pennsylvania



## Register Now!

For more information and to register, visit:

[www.medscape.org/sympo/heart-failure-sglt-inhibition](http://www.medscape.org/sympo/heart-failure-sglt-inhibition)

THIS SATELLITE SYMPOSIUM IS PRESENTED THROUGH A COLLABORATION BETWEEN  
MEDSCAPE CARDIOLOGY AND THE HEART FAILURE SOCIETY OF AMERICA.

THE PROGRAM TOPIC, LEARNING OBJECTIVES, AND FACULTY HAVE BEEN REVIEWED AND APPROVED  
BY THE ASM SATELLITE REVIEW COMMITTEE. SATELLITE SESSIONS ARE NOT A PART OF THE SCIENTIFIC  
PROGRAM AS PLANNED AND EXECUTED BY THE HFSA PROGRAM COMMITTEE.

## TARGET AUDIENCE

This activity is intended for cardiologists, primary care physicians, emergency medicine physicians, diabetologists/endocrinologists, nurse practitioners, nurses, physician assistants, and pharmacists.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Role of SGLT inhibition in the care of patients with HF
  - Latest clinical safety and efficacy data for SGLT inhibition in patients with HF
  - Economic impact of SGLT inhibition in the care of patients with HF

Have greater competence related to

- Appropriate SGLT inhibition in patients across the spectrum of HF

## ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### For Physicians

Medscape, LLC designates this live activity for a maximum of **1.0 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.

### For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-216-L01-P).

## AGENDA

**7:15 AM**

Welcome and Introductions  
Zachary Cox, PharmD

**7:20 AM**

Presentations:

*Understanding SGLT Inhibition and HF*

Biykem Bozkurt, MD, PhD

*Digging Deep Into the Clinical Safety and Efficacy of SGLT Inhibition*

Zachary Cox, PharmD

*Practical Considerations for SGLT Inhibition in HF*

Ileana L Piña, MD, MPH

**8:05 PM**

Panel Discussion and Q&A



For more information and to register, visit:

[www.medscape.org/sympo/heart-failure-sgl-t-inhibition](http://www.medscape.org/sympo/heart-failure-sgl-t-inhibition)